USPTO 2015–2025 USPTO PatentsView US Corporation

Sofregen Medical, Inc.

USPTO PatentsView assignee record - 6 granted patents across 5 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C08K (Use of inorganic or non-macromolecular organic substances as compounding ingredients).

RSS updates for this company

The verdict

According to USPTO PatentsView, Sofregen ranks #43,191 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 5 technology areas.

#43,191
of 49,997 US assignees by volume
Top 25%
by Innovation Score (44.7/100)
16.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R43191 · US Corporation #43,191 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 6 grants
  • LOWER-Q #43,191/49,997
  • PHOTO-FINISH Smiths Group
  • CPC-NARROW C08K · 5 areas
  • INNOV-PAR 44.7/100
  • CLAIMS-RICH 16.8 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2020–2025 · 6y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Smiths Group PLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Sofregen

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Sofregen's Innovation Score is 44.7/100 (top 25% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Sofregen's grants concentrate

Sofregen Medical, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 83.3% of grants classified under C08K (Use of inorganic or non-macromolecular organic substances as compounding ingredients). Peak complete grant year is 2023 (4 grants) versus a trough of 1 in 2020. By volume, Sofregen sits between Smiths Group PLC and Solace Systems, Inc..

Sofregen's three-year grant acceleration

Sofregen Medical, Inc. shows 4 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Sofregen's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Sofregen holds 6 patents at rank #43,291, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Sofregen

By rank, the assignees closest to #43,291 in granted patent volume.

Leaders in C08K (Use of inorganic or non-macromolecular organic substances…)

Other assignees with the most granted patents in Sofregen's primary technology class.

Sofregen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

45 Top 25% higher than 75% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 202020232025 1
USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table
Sofregen Medical, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2020 1 16.7%
2023 4 66.7%
2025partial year 1 16.7%

Where it ranks

Overall rank by patents

#43,191

of 49,997 tracked assignees

Innovation Score

44.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Sofregen Medical, Inc.'s patent record in context - here's where to go next.

  • Sofregen Medical, Inc.'s lead technology class is C08K (Use of inorganic or non-macromolecular organic substances as compounding ingredients), 83.3% of its portfolio - see every assignee active in that class. Explore C08K
  • Ranked #43,191 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Sofregen Medical, Inc. against Smiths Group PLC, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 44.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.